New drug combo targets brain metastases in HER2-Positive cancers

NCT ID NCT05673928

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether two drugs, tucatinib and T-DM1, can control HER2-positive solid tumors that have spread to the brain. About 30 participants will receive both drugs, and researchers will monitor side effects and how well the treatment works. The goal is to find a better option for people with this challenging condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tucatinib and trastuzumab emtansine (T-DM1)
What this could lead to: If successful, this combination could offer a new treatment option for people with HER2-positive cancers that have spread to the brain, potentially helping to control the disease.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Side effects from the drug combination could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm metastatic malignant neoplasm in the brain Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES METASTATIC SOLID TUMOR

Contacts and locations

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.